Steatohepatitis/Metabolic Liver Disease

Top Story

Take Home from NASH-TAG: On the precipice of the fatty liver pipeline

Take Home from NASH-TAG: On the precipice of the fatty liver pipeline
January 18, 2019

Lipocine NASH prodrug shows liver fat reduction in ongoing study

January 17, 2019
Lipocine announced top-line interim results from an ongoing study of LPCN 1144, an oral prodrug of bioidentical testosterone designed for the treatment of nonalcoholic…
In the Journals

Stress, environment key barriers to Mediterranean diet uptake for NAFLD

January 14, 2019
Barriers to initiating a Mediterranean diet — shown to improve liver health in patients with nonalcoholic fatty liver disease — included an obesogenic…

ChemomAb doses first patient in phase 1 NAFLD trial

January 14, 2019
ChemomAb dosed the first patient in a phase 1b repeated-dose clinical trial of CM-101 for treating patients with nonalcoholic fatty liver disease and nonalcoholic…
More Headlines »

Cirrhosis and Hepatic Encephalopathy – Managing Their Consequences and Complications

This activity is supported by an educational grant from Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC.

Cirrhosis, or advanced fibrosis of the liver, can lead to serious health sequelae or death. However, substantial…
More »
GI Bookshelf

Question 28: I Have A Patient With Biliary-Type Pain, But No Other Evidence Of Bile Duct Disease (Normal Diameter Duct On Ultrasound, Normal Liver Function Tests). How Should Such A Patient Be Managed?

From Curbside Consultation in Endoscopy: 49 Clinical Questions, Second Edition
More »
Meeting News

Expert reviews clinical liver disease take-aways from DDW 2018

June 5, 2018
More »